

2015 Annual General Meeting: CEO Address

Dr Ross Macdonald, CEO, Cynata Therapeutics Limited

November, 2015



Copyright and Confidential

Important information

This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata Therapeutics, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).



Cynata Therapeutics Ltd: Our Business

- ASX-listed company (CYP): November 2013
- ~1900 shareholders; 72.7m shares
- Market cap: \$32m (10 Nov '15)
- 52 week range: \$0.32-\$1.44



- Focus: Stem cells and regenerative medicine
 - Commercial development of mesenchymal stem cells (MSC) for therapeutic use
 - Cymerus™: unique product manufacturing platform
 - utilises induced Pluripotent Stem Cells (iPSCs)
 - "Off the Shelf" medicine
 - Not derived from embryos
 - Derived from a single donor for universal use (allogeneic)

Why are Mesenchymal Stem Cells (MSCs) Important?

- Regenerative medicine is a revolution: potential to resolve unmet medical needs by addressing the underlying causes of disease
- For example: heart attack (MI)
 - Sudden block of blood flow to a section of heart muscle
 - Most occur as a result of coronary heart disease (CHD): plaque build up inside the coronary arteries
 - Cholesterol lowering medicines ("statins") reduce CHD
 - BUT current medicines do NOT address the scar tissue that replaces healthy heart muscle after a heart attack
 - MSCs are being extensively investigated as a potential therapeutic approach for cardiac regeneration after MI, eg Cynata's University of Sydney collaboration



Heart disease facts

- Coronary heart disease is the biggest single cause of death in the UK
- It kills about 150,000 people every year, 21,000 of which are under 65
- About 300,000 people suffer heart attacks each year
- Two million people suffer angina
- It costs the UK economy about £10bn a year

Why are Mesenchymal Stem Cells (MSCs) Important?

Around 300* clinical trials underway with MSC therapies:





Cymerus Competitive Advantage

- All current MSC-based medicines require donor derived material
 - Bone marrow
 - Adipose tissue
 - Placenta



- Yield of MSCs is low, eg bone marrow harvest \rightarrow ~20 thousand cells
- Typical dose is >100 **million** cells
- How can enough be produced?



Cymerus Competitive Advantage

- Cell expansion is used to create the quantities needed
- Sounds simple?
- BUT, MSCs exhibit changes during expansion, including altered phenotype, differentiation potential, gene expression profile
- This occurs after as few as 13 population doublings, equivalent to ~ 1.6 doses
- Maybe lots of donors would suffice?



...then eight and so on ...



Cymerus Competitive Advantage



- Multiple donors are not a practical solution for scalable manufacture
- The solution lies in a different starting material to provide a virtually limitless source of MSCs without excessively expanding the MSCs in culture

Cynata's Cymerus™ technology



- Cymerus[™] process uses iPSCs as starting material to mass produce MSCs
- iPSCs: adult-derived cells with embryonic-like properties – effectively limitless expansion potential; ability to differentiate into any cell type
- Inventors include:
 - Prof James Thomson derived first human embryonic stem cell line in 1998 and human induced pluripotent stem cells (iPSCs) in 2007
 - Prof Igor Slukvin, co-founder of Cynata and author of >70 publications in the stem cell field



(Cell Stem Cell (2010) 7;718–729)

(9) Cell Stem Cell Article

A Mesoderm-Derived Precursor for Mesenchymal Stem and Endothelial Cells

Maxim A. Vodyanik,¹ Junying Yu,¹ Xin Zhang,² Shulan Tian,³ Ron Stewart,³ James A. Thomson,^{1,3} and Igor I. Slukvin^{1,4,*}





Business Strategy

- Cymerus technology is relevant to all potential therapeutic uses for MSCs
- Logical to seek to partner the technology: resources, expertise, cash and market access
- GMP manufacturing milestone in February facilitated commercial discussions
- Vibrant deal landscape
 - CDI and Fujifilm
 - Athersys and Chugai
 - MSB and Celgene
 - Gamida Cell and Novartis
 - Ocata and Astellas
- Goal to secure at least one commercial alliance in 2015

Cynata Therapeutics: The Past 12 Months

• Consolidating a commercial and clinical path:

- December 2014 options exercised yielding \$2.9m gross
- Further validation through UWA, University of Sydney and Harvard/MGH collaborations
- Validation of up-scaled manufacturing process in a GMP environment: major milestone
- Engagement of US investor relations and PR firm
- Invited presenter at major international regenerative medicine and investor conferences
- Formal interaction with regulatory agencies
- Research coverage by leading US-based independent equity research and corporate access firm: A\$1.55 price target
- Strengthened the balance sheet with a \$5m (gross) placement to US investors
- Engaged CRO to conduct the Phase 1 clinical trial
- Appointment of John Chiplin to the Board



Cynata: The Year Ahead

- Important Development Milestones and Value Drivers:
 - Continue our partnering activities
 - Commence Phase 1 clinical trial of CYP-001 in GvHD
 - Vigorous investor relations campaign
 - Assessment of off-shore listing opportunities
 - Data from pre-clinical program and PoC studies
 - Strengthen our patent portfolio





A Next Generation Stem Cell Company

Modified Stem Cells: The Future of Cancer Treatment

Kilian Kelly, PhD Vice President, Product Development November 2015



Copyright and Confidential

Unmodified MSCs

- MSCs have a natural ability to:
 - home to sites of inflammation/injury
 - modulate the immune system
 - secrete bioactive molecules
- Potentially effective for a wide range of conditions, including:
 - GvHD
 - Heart attacks, heart failure
 - Stroke
 - Diabetes
 - Degenerative disc disease
 - Arthritis
- ¹⁴ And numerous others



1. Eggenhofer et al. Front Immunol. (2014) 19;5:148



Modified MSCs: rationale

- In addition to their natural functions, MSCs can also be modified to target other diseases, including cancer
- MSCs are known to home to tumours, so MSCs modified to secrete cancer-killing toxins can be used to release anticancer agents where they are needed
- \rightarrow This could facilitate selective killing of cancer cells, without affecting normal cells, which could improve efficacy with reduce side effects

 \rightarrow Could be especially useful for inaccessible cancers, such as brain tumours

 \rightarrow A similar approach can be taken with other drugs/bioactive molecules to target other diseases

therapeutics

The potential of modified MSCs





Cancer-killing stem cells engineered in lab

O 25 October 2014 Health

Scientists from Harvard Medical School have discovered a way of turning stem cells into killing machines to fight brain cancer.



Home » September » Genetically Engineered Stem Cells Could Be Tomorrow's Cancer Treatment

FROM THE SEPTEMBER 2015 ISSUE

Genetically Engineered Stem Cells Could Be Tomorrow's Cancer Treatment

Stem cells can serve as delivery vehicles for tumoreradicating drugs.

News - Technology & Science - Cancer

Stem cell technology can mass-produce cancer-killing cells to target tumours

FierceDrugDelivery

NEWS TOPICS ANALYSIS

Topics: R&D

Harvard team uses stem cells to deliver toxic doses to cancer cells

October 29, 2014 | By Michael Gibney

SHARE Email

Researchers at Harvard have programmed stem cells embedded in a mouse tumor to deliver a toxic dose of cytotoxins, killing the cancer cells from the inside. The research was published in the journal *Stem Cells*.



Cynata's collaboration with Harvard

- Cynata has commenced a collaboration with Dr Khalid Shah, of Massachusetts General Hospital, Harvard Medical School and Harvard Stem Cell Institute
- Dr Shah's team are pioneers of technology to modify stem cells to secrete cancer-killing toxins
- Particular focus on glioblastoma (brain tumour) one of the most difficult types of cancer to treat: 2 year survival is currently just 30%, with 5 year survival just 10%









Modified Stem Cells to Treat Brain Tumours



- Dr Shah's group has previously found that modified stem cells killed cancer cells and prolonged survival in a clinically relevant animal model of glioblastoma (brain tumours)
- Dr Shah's group are now investigating similar modification of Cynata's Cymerus[™] MSCs, as a first step in a potential additional clinical development program

therapeutics

Investor interest

- Immense investor interest in cell-based therapies for cancer
- Last week, Cellectis announced data from <u>a single patient</u> treated with their cell-based therapy for leukaemia, which resulted in a ~60% increase in share-price
- Note: Cynata's new program targets solid tumours, unlike most other cell-based cancer therapies, which target blood cancers





Thank you for your attention

CUNDTO therapeutics